Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Polio vaccine showdown: which sequence protects best?

NCT ID NCT07457060

Vaccine Sponsor: Sinovac Biotech Co., Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two types of inactivated polio vaccine (Sabin strain and wild strain) given in different orders to 480 infants aged 2 months. The goal is to see which sequence triggers the best immune response and causes the fewest side effects. Participants will receive three doses via injection, either into muscle or under the skin.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Inactivated poliovirus vaccine (Sabin strain and wild strain)
What this could lead to
If successful, this could help optimize polio vaccination schedules to improve protection and reduce side effects.
What could go wrong
This is a Phase 4 study, so the vaccines are already approved; the main question is which sequence works best. Results may not apply to all populations.
Why investors are watching

Sinovac Biotech is running a Phase 4 trial comparing two ways of giving its inactivated polio vaccine, either under the skin or into the muscle, in 480 participants. For a small company, this readout matters because it tests whether the vaccine works and is safe when given by a different route, which could support broader use or regulatory approvals. A clear result could strengthen the vaccine's profile, while a poor outcome could raise questions about the product's reliability.

If it works: A positive result showing the vaccine is safe and triggers a good immune response by both injection routes could help Sinovac position the vaccine for wider distribution or new market approvals. It may also reassure regulators and buyers that the product performs consistently.

If it fails: If the trial shows one route is less effective or causes more side effects, Sinovac may need to change how it recommends the vaccine, which could delay adoption or require extra studies. Clinical trials often fail to meet their goals, so investors should treat the outcome as uncertain.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 480 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

56 to 84 days

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Infants of 2 months old (aged 56-84 days). 2. Have a parent/legal guardian who has provided written informed consent after being fully informed about the study. 3. Be able to provide the vaccination records since birth. 4. The infant's mother is tested negative for HIV, syphilis, hepatitis B, and hepatitis C during or before the infant's enrollment to this study (test results obtained during pregnancy are acceptable, if provided). Exclusion Criteria: 1. History of any polio vaccination. 2. History of severe allergic reaction to previous vaccinations or hypersensitivity to any vaccine component. 3. Premature infants (born before week 37 of gestation). 4. History of asphyxia rescue or nervous system injury. 5. Congenital malformations, developmental disorders, clinically significant genetic defects, severe malnutrition. 6. Autoimmune diseases or immunodeficiency/immunosuppression. 7. Serious chronic diseases such as Down's syndrome, diabetes, sickle cell anemia, or neurological disorders. 8. Abnormal coagulation functions (e.g., coagulation factor deficiency, blood coagulation diseases, platelet disorders). 9. Received immunosuppressant (excluding topical or inhaled corticosteroids), cytotoxic drug, or other immunomodulatory therapies. 10. Received blood products before trial vaccine inoculation. 11. Received other study drugs within 30 days before enrollment. 12. Received live attenuated vaccines within 14 days before enrollment. 13. Received subunit or inactivated vaccines within 7 days before enrollment. 14. Acute diseases or acute exacerbations of chronic diseases within 7 days before enrollment. 15. Significant acute diseases, chronic infections, or axillary temperature ≥ 37.5°C before enrollment. 16. Any other factors deemed by the investigators as unsuitable for participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Poliomyelitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

poliomyelitis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Poliomyelitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    3 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centennial Clindev Research and Development of Medical Sciences

    RECRUITING

    Kawit, Cavite, Philippines

    Contact Email: •••••@•••••

  • Health Index Multispecialty Clinic - Research and Development on Medical Sciences

    RECRUITING

    Imus, Philippines

  • Iloilo Doctors' Hospital

    RECRUITING

    Iloilo City, Philippines

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.